The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer.

ABSTRACT: Breast tumors often display extreme genetic heterogeneity characterized by hundreds of gross chromosomal aberrations and tens of thousands of somatic mutations. Tumor evolution is thought to be ongoing and driven by multiple mutagenic processes. A major outstanding question is whether primary tumors have preexisting mutations for therapy resistance or whether additional DNA damage and mutagenesis are necessary. Drug resistance is a key measure of tumor evolvability. If a resistance mutation preexists at the time of primary tumor presentation, then the intended therapy is likely to fail. However, if resistance does not preexist, then ongoing mutational processes still have the potential to undermine therapeutic efficacy. The antiviral enzyme APOBEC3B (apolipoprotein B mRNA-editing enzyme, c

SUBMITTER: Law EK 

PROVIDER: S-EPMC5055383 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature